Can this consent be signed electronically?

Yes. Electronic signatures are legally valid under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided intent, consent, attribution, and record retention criteria are met.

Is HIPAA protection required for eConsent?

Yes. Because the form contains protected health information, use a HIPAA-compliant platform and execute a Business Associate Agreement (BAA) with the eSignature vendor.

When is a witness or notary required?

Witness or notary requirements depend on state law and institutional policy; some states or specific consent types may require witnesses or notarization before administration.

What if the patient cannot sign?

Document incapacity, obtain signature from an authorized representative, and record the representative’s authority; follow applicable state durable power of attorney or guardianship rules.

How long should the signed form be retained?

Retain per HIPAA six-year minimum (45 CFR §164.530(j)) and institutional retention policies; financial or tax-related records may require different retention periods.

Does the ESIGN consumer disclosure apply?

If the consent is provided electronically to a consumer, provide the ESIGN-required disclosure explaining the right to paper copies, access requirements, and how to withdraw consent.

Electronic Signature
Templates
Healthcare
Healthcare Patient Consent Form for Bisphosphonates

Healthcare Patient Consent Form for Bisphosphonates

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Healthcare Patient Consent Form for Bisphosphonates

Patient Information

Patient Name: Date of Birth: Gender: Address: Primary Phone:

Emergency Contact

Contact Name: Relationship: Contact Phone:

Insurance Information

Insurance Provider: Policy Number: Group Number: Subscriber Name:

Medical History

Current Medications: Allergies: Prior Surgeries / Hospitalizations: Chronic Conditions:

Prior exposure to bisphosphonates: Oral Intravenous None/Unknown

Known renal impairment or reduced kidney function: Yes No

Proposed Treatment

Description: The patient is being offered bisphosphonate therapy to treat osteoporosis, metastatic bone disease, or other indicated bone-resorptive disorders. Treatment may be administered orally or by intravenous infusion depending on the clinical plan.

Intended treatment type: Oral bisphosphonate Intravenous bisphosphonate

Planned Treatment Date: Dose / Frequency (if known):

Risks, Benefits, and Alternatives

Benefits: Bisphosphonates may reduce bone pain, decrease fracture risk in osteoporosis, and slow skeletal complications associated with bone metastases. Expected benefits were explained to me by my clinician.

Material risks and potential adverse events of bisphosphonate therapy include, without limitation: osteonecrosis of the jaw (ONJ) which may be severe and persist despite treatment; atypical femoral fractures; acute phase reactions (fever, myalgia); hypocalcemia which may be serious; esophageal irritation or ulceration with oral agents; renal deterioration with certain intravenous agents; ocular inflammation; and rare but serious allergic reactions. Some adverse effects may be irreversible.

Alternatives: Alternatives include no bisphosphonate treatment, alternative pharmacologic options, or non-pharmacologic management. The clinician has discussed alternatives, expected outcomes, and the option to withdraw consent at any time prior to administration.

I acknowledge that the risks, benefits, and alternatives have been explained to me and I have had the opportunity to ask questions. I understand that not all possible complications can be listed and that the clinician cannot guarantee a specific outcome.

I acknowledge that the risks, benefits, and alternatives were explained to me and my questions were answered.

Dental Precautions and Pregnancy

There is an increased risk of osteonecrosis of the jaw associated with bisphosphonate use. A dental examination and completion of invasive dental work are recommended prior to initiation when clinically feasible. If dental procedures are required during treatment, appropriate coordination with dental providers is advised.

Women of childbearing potential must inform their clinician if they are pregnant, plan to become pregnant, or are breastfeeding. Bisphosphonates may cause fetal harm and are not recommended during pregnancy.

I have been advised to have a dental evaluation prior to treatment or to inform the treating clinician of any planned dental work.

Informed Consent and Authorization

By signing below I certify that I am the patient or the patient’s legal representative, that I have read and understand the information provided in this form, that the nature and purpose of the proposed bisphosphonate treatment, the foreseeable risks (including but not limited to those set forth above), and reasonable alternatives have been explained to me in terms I understand, and that my questions have been answered to my satisfaction. I consent to administration of the bisphosphonate therapy as described.

I authorize the release of medical information to other healthcare providers and to my insurance carrier as necessary for treatment, payment, and healthcare operations related to this therapy.

Patient Initials: Authorization Expiration Date:

HIPAA / Privacy Acknowledgment

I acknowledge receipt of the facility's privacy practices and understand that my protected health information may be used and disclosed for treatment, payment, and health care operations as permitted by applicable law. I authorize disclosure of necessary health information related to this treatment to other healthcare providers and to my insurer.

I acknowledge the privacy practices and authorize use/disclosure as described above.

Patient Declaration

I understand that I may refuse or withdraw consent at any time prior to administration of the medication. Withdrawal of consent will be documented in my medical record and discussed with me. If I withdraw consent after initiation, I understand that there may be clinical consequences which I discussed with my clinician.

Patient Printed Name:

Relationship (if signing for patient):

Signature:

Date:

What the Healthcare Patient Consent Form for Bisphosphonates Is

The Healthcare Patient Consent Form for Bisphosphonates documents a patient’s informed agreement to receive bisphosphonate therapy, including diagnosis, intended benefit, known risks (for example, osteonecrosis of the jaw), alternatives, and follow-up obligations. It serves as a clinical and legal record that the clinician explained risks and benefits, the patient asked questions, and consent was given in writing, dated, and signed by the authorized parties. The form is commonly used in oncology, endocrinology, dental clearance workflows, and outpatient infusion settings to ensure shared decision-making and regulatory compliance.

Why a Clear Consent Form Matters for Bisphosphonate Care

A complete consent form documents informed choice, reduces clinical and legal risk, supports coordination with dental and specialty care, and creates an auditable record that can be retained and reproduced under ESIGN and HIPAA rules.

Who Typically Completes or Signs This Consent Form

The form is used by providers and staff to capture patient permission and by patients or authorized representatives to record consent.

Adult patients receiving or considering bisphosphonate therapy for osteoporosis or metastatic bone disease
Prescribing clinicians (e.g., oncologists, endocrinologists, primary care physicians) and delegated clinical staff
Authorized representatives or legal guardians when the patient lacks decisional capacity

Completed forms are kept in the medical record and shared with treating clinicians and, when applicable, the patient’s dentist or specialist for coordinated care.

Roles and Who Signs

Patient

The patient (or authorized representative) signs to confirm understanding of risks, benefits, and alternatives. The narrative should document any questions asked and any additional verbal counseling provided by staff, including dental recommendations.

Prescribing Clinician

The clinician or authorized prescriber documents diagnosis, rationale for bisphosphonate therapy, discussed risks such as osteonecrosis of the jaw, and signs to attest that informed consent discussion occurred.

Step-by-Step: Filling Out the Consent Form

Follow these sequential steps to capture a complete, auditable consent record before initiating bisphosphonate therapy.

01

Review Indication: Confirm diagnosis and medical necessity with chart review.
02

Explain Risks: Describe common and serious risks, including osteonecrosis and atypical fractures.
03

Discuss Alternatives: Document nonpharmacologic options and alternative therapies discussed.
04

Obtain Signature: Have patient sign and date; note any representative or witness.

Configuring the Consent Form for Online Completion

When configuring a digital consent workflow, choose authentication, conditional fields, and storage settings that align with clinical and legal requirements.

Form Template	Create a reusable template with required fields and clinician signoff sections
Signer Authentication	Use email plus SMS code or ID verification for higher assurance
Conditional Fields	Show dental clearance fields only when patient indicates prior dental work
Audit Trail	Enable timestamp, IP, and action history capture for legal evidence
Storage Location	Save to encrypted clinical record or specified secure cloud folder

How the eConsent Workflow Typically Operates

A straightforward eConsent flow minimizes patient friction while preserving legal sufficiency and an audit trail for later review.

Sender Uploads: Staff uploads the consent form and sets signer roles.
Patient Notification: Patient receives a secure email or SMS link to review.
Sign and Date: Patient signs, dates, and confirms understanding online.
Record Stored: Signed PDF and audit trail saved to the EHR or secure archive.

Technical Considerations for eSigning and Storage

Choose a platform that supports HIPAA controls, common file formats, and integrations with your record systems.

File Formats: Support for PDF and DOCX is important for compatibility.
Integrations: Connectors to EHRs or cloud storage simplify recordkeeping.
Mobile Support: Patient mobile signing reduces delays in outpatient settings.

Essential Sections to Include on a Professional Consent Form

A comprehensive consent form balances clinical detail with plain-language explanations so patients can make an informed decision.

Patient Identification

Full legal name, date of birth, and medical record number to avoid misidentification and link the consent to the correct chart.

Therapy Details

Exact drug name, dose, route, frequency, and planned duration so administration staff have clear instructions.

Risks and Side Effects

List common and severe adverse events in plain language, including risk of osteonecrosis of the jaw and atypical femur fracture.

Alternatives and Benefits

Describe nonpharmacologic options, alternative medications, and expected clinical benefits of bisphosphonate therapy.

Dental Recommendations

Note any required dental evaluation, timing relative to therapy, and steps to mitigate jaw osteonecrosis risk.

Signatures and Dates

Signature lines for patient, clinician, and witness if required, with date fields and space for representative details if applicable.

Security and Compliance Essentials to Capture

HIPAA: Protects PHI; BAA required for vendors

ESIGN / UETA: Legal validity for electronic signatures

Audit Trail: Timestamp, IP, and signer actions recorded

Encryption: TLS in transit and AES-256 at rest

Access Controls: Role-based permissions for staff access

BAA Requirement: Execute a BAA with eSignature provider

Common Preparation Errors to Avoid

Failing to document dental clearance dates and recommendations increases clinical risk and can complicate post-treatment care decisions.
Using vague medication entries (for example, 'bisphosphonate') rather than listing the specific product, dose, and route can lead to administration errors.
Not recording whether the signer is an authorized representative or lacks capacity creates ambiguity and may render consent legally insufficient.
Skipping the required ESIGN consumer disclosure for patient-facing electronic consents can undermine the enforceability of an electronic signature.

Timing and When the Form Must Be Completed

Timely completion ensures safe care sequencing — document consent well before the first scheduled dose and before dental procedures that could affect risk.

Before First Dose:

Consent should be documented prior to administering the initial bisphosphonate dose.

Dental Clearance Timing:

If dental work is anticipated, obtain clearance and record it before starting therapy.

Procedure Scheduling:

For infusion centers, schedule consent completion at pre-infusion assessment visits.

Urgent Situations:

Document verbal consent and follow up with written consent as soon as feasible.

Record Start Date:

The effective consent date starts retention timelines and statute-of-limitations clocks.

Consequences of Incomplete or Incorrect Consent

Clinical Harm: Delayed dental care or missed warnings

Legal Exposure: Malpractice or informed consent claims

Regulatory Risk: HIPAA or state reporting issues

Insurance Denial: Coverage disputes for non-documented necessity

Record Rejection: Unsigned or undated forms may be invalid

Patient Distrust: Erodes confidence in care team

eSignature Vendor Pricing Snapshot for Healthcare Consent Workflows

Comparing common vendor starting prices and core capabilities relevant to healthcare workflows; signNow is listed first per platform comparisons.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	No	No	Yes, limited	Yes, limited
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Real-World Use Cases for the Consent Form

These examples show how clinics and dental offices integrate the form into patient care and documentation workflows.

Outpatient Infusion Center

Clinic completes the consent during pre-infusion assessment

Staff documents dental clearance status
The signed PDF and audit trail are stored in the EHR for future reference and billing compliance.

Dental Clearance Workflow

Dentist documents oral exam and any planned extractions

Dentist notes timing relative to bisphosphonate dosing
Clinic uses that record to confirm clearance and proceed with therapy scheduling.

Best Practices for Accurate, Efficient Consent Capture

Adopt standardized language, clear workflows, and secure eSignature tools to reduce risk and improve patient understanding.

Standardize the Template

Use a single institution-approved template that includes explicit dental screening items, clear risk descriptions, and designated signature blocks to prevent omissions and inconsistencies across providers.

Train Staff on Documentation

Ensure nurses and clinicians know how to complete fields correctly, verify identity, and record representative status; consistent training reduces incomplete captures and administrative burden.

Implement Strong Authentication

For patient-facing eConsents, require two-factor or identity-proofing when higher assurance is needed and document the authentication method in the audit trail for legal defensibility.

Retain and Index Records

Store signed consents with the patient chart, index by date and treatment, and maintain retention schedules consistent with HIPAA and applicable state rules to support audits and future care continuity.

Frequently Asked Questions About Bisphosphonate Consent Forms

Answers to common questions about legal validity, required fields, electronic signing, and recordkeeping for bisphosphonate consent.

Need help? Contact support

Can this consent be signed electronically?
Yes. Electronic signatures are legally valid under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided intent, consent, attribution, and record retention criteria are met.
Is HIPAA protection required for eConsent?
Yes. Because the form contains protected health information, use a HIPAA-compliant platform and execute a Business Associate Agreement (BAA) with the eSignature vendor.
When is a witness or notary required?
Witness or notary requirements depend on state law and institutional policy; some states or specific consent types may require witnesses or notarization before administration.
What if the patient cannot sign?
Document incapacity, obtain signature from an authorized representative, and record the representative’s authority; follow applicable state durable power of attorney or guardianship rules.
How long should the signed form be retained?
Retain per HIPAA six-year minimum (45 CFR §164.530(j)) and institutional retention policies; financial or tax-related records may require different retention periods.
Does the ESIGN consumer disclosure apply?
If the consent is provided electronically to a consumer, provide the ESIGN-required disclosure explaining the right to paper copies, access requirements, and how to withdraw consent.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now